{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T14:04:47Z","timestamp":1791986687938,"version":"4.4.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2024,1,27]],"date-time":"2024-01-27T00:00:00Z","timestamp":1706313600000},"content-version":"vor","delay-in-days":1152,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T00:00:00Z","timestamp":1621382400000},"content-version":"vor","delay-in-days":169,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["asbmr.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>A rebound of osteoclast activity during the 2\u2009years after a treatment or prevention of osteoporosis with denosumab (Dmab) leads to an increased risk of vertebral fractures (VFs). We attempted to identify the risk factors for these VF and to examine the protective role of bisphosphonates. For that, 22 specialists in Switzerland provided data of unselected patients, treated with denosumab for osteoporosis or breast cancer without metastases under aromatase inhibitors, who have received at least two injections of Dmab, with at least 1\u2009year of follow-up after discontinuation. The questionnaire covered separately the periods before, during, and after Dmab treatment, and registered clinical, radiological, and lab data. For the analysis of the risk factors, the main outcomes were the time to the first VF after the treatment, the presence of multiple VFs (MVFs), and the number of VFs. The incidence of VF was 16.4% before, 2.2% during, and 10.3% after the treatment with Dmab. The risk of VF after Dmab discontinuation was associated with an increased risk of non-vertebral fractures. The pretreatment predictors of the post-treatment fracture risk were a parental hip fracture and previous VFs. Further risk factors appeared later, such as low total hip bone mineral density (BMD) during and after denosumab, increased bone resorption markers, and the loss of total hip BMD after the denosumab. Treatment with bisphosphonates, especially after Dmab, had a protective effect. Bisphosphonates given before Dmab did not further decrease the risk of VF in cases who got bisphosphonates after Dmab. This study shows that the risk of VF is poorly predictable before the prescription of denosumab. But during and after the treatment, bone resorption markers and BMD have a significant predictive value. Bisphosphonates after the treatment with denosumab are protective against VFs. \u00a9 2021 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).<\/jats:p>","DOI":"10.1002\/jbmr.4335","type":"journal-article","created":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T12:39:58Z","timestamp":1621427998000},"page":"1717-1728","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":120,"title":["Fractures After Denosumab Discontinuation: A Retrospective Study of 797 Cases"],"prefix":"10.1093","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8857-8664","authenticated-orcid":false,"given":"Peter","family":"Burckhardt","sequence":"first","affiliation":[{"name":"Clinic Bois Cerf\/Hirslanden Lausanne Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2084-3235","authenticated-orcid":false,"given":"Mohamed","family":"Faouzi","sequence":"additional","affiliation":[{"name":"University Center for Primary Care and Public Health Biostatistics Lausanne Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0639-5536","authenticated-orcid":false,"given":"Thierry","family":"Buclin","sequence":"additional","affiliation":[{"name":"University Institute of Clinical Pharmacology Lausanne Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3684-2376","authenticated-orcid":false,"given":"Olivier","family":"Lamy","sequence":"additional","affiliation":[{"name":"University Hospital CHUV Lausanne Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"and the Swiss Denosumab Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,5,19]]},"reference":[{"issue":"2","key":"2024012713453873500_jbmr4335-bib-0001","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","article-title":"Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial","volume":"43","author":"Miller","year":"2008","journal-title":"Bone."},{"issue":"4","key":"2024012713453873500_jbmr4335-bib-0002","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"key":"2024012713453873500_jbmr4335-bib-0003","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1007\/s00198-017-3919-1","article-title":"Observations following discontinuation of long-term denosumab therapy","volume":"28","author":"McClung","year":"2017","journal-title":"Osteoporos Int."},{"issue":"1","key":"2024012713453873500_jbmr4335-bib-0004","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00198-017-4242-6","article-title":"Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study","volume":"29","author":"Zanchetta","year":"2018","journal-title":"Osteoporos Int."},{"issue":"5","key":"2024012713453873500_jbmr4335-bib-0005","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1007\/s00198-015-3458-6","article-title":"Rebound-associated vertebral fractures after discontinuation of denosumab\u2014from clinic and biomechanics","volume":"27","author":"Popp","year":"2016","journal-title":"Osteoporos Int."},{"key":"2024012713453873500_jbmr4335-bib-0006","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/jbmr.448","article-title":"Bone remodeling in postmenopausal women who discontinued denosumab treatment: off-treatment biopsy study","volume":"11","author":"Brown","year":"2011","journal-title":"J Bone Miner Res."},{"key":"2024012713453873500_jbmr4335-bib-0007","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/jbmr.1808","article-title":"Discontinuation of denosumab and associated fracture incidence: analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial","volume":"28","author":"Brown","year":"2013","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2024012713453873500_jbmr4335-bib-0008","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00198-015-3380-y","article-title":"Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports","volume":"27","author":"Aubry-Rozier","year":"2016","journal-title":"Osteoporos Int."},{"issue":"5","key":"2024012713453873500_jbmr4335-bib-0009","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1007\/s00198-015-3459-5","article-title":"Multiple clinical vertebral fractures following denosumab discontinuation","volume":"27","author":"Anastasilakis","year":"2016","journal-title":"Osteoporos Int."},{"issue":"1","key":"2024012713453873500_jbmr4335-bib-0010","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s12020-016-1030-6","article-title":"Clinical vertebral fractures following denosumab discontinuation","volume":"54","author":"Polyzos","year":"2016","journal-title":"Endocrine."},{"key":"2024012713453873500_jbmr4335-bib-0011","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1210\/jc.2016-3170","article-title":"Severe rebound-associated vertebral fractures after denosumab discontinuation: nine clinical cases report","volume":"102","author":"Lamy","year":"2017","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"2024012713453873500_jbmr4335-bib-0012","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/jbmr.3110","article-title":"Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases","volume":"32","author":"Anastasilakis","year":"2017","journal-title":"J Bone Miner Res."},{"issue":"1","key":"2024012713453873500_jbmr4335-bib-0013","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s00223-018-0389-1","article-title":"Previous treatment with bisphosphonate did not protect from this phenomenon. Vertebral fractures following denosumab discontinuation in patients with prolonged exposure to bisphosphonates","volume":"103","author":"Tripto-Shkolnik","year":"2018","journal-title":"Calcif Tissue Int."},{"key":"2024012713453873500_jbmr4335-bib-0014","first-page":"480","author":"Fernandez","year":"2020"},{"issue":"2","key":"2024012713453873500_jbmr4335-bib-0015","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.semarthrit.2019.02.007","article-title":"Spontaneous vertebral fractures after denosumab discontinuation: a case collection and review of the literature","volume":"49","author":"Florez","year":"2019","journal-title":"Semin Arthrit Rheumat."},{"issue":"1","key":"2024012713453873500_jbmr4335-bib-0016","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10549-019-05458-8","article-title":"Sixty spontaneous vertebral fractures after denosumab discontinuation in 15 women with early-stage breast cancer under aromatase inhibitors","volume":"179","author":"Gonzalez-Rodriguez","year":"2020","journal-title":"Breast Cancer Res Treat."},{"issue":"2","key":"2024012713453873500_jbmr4335-bib-0017","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J Bone Miner Res."},{"issue":"1","key":"2024012713453873500_jbmr4335-bib-0018","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11914-019-00502-4","article-title":"Stopping denosumab","volume":"17","author":"Lamy","year":"2019","journal-title":"Curr Osteoporos Rep."},{"issue":"11","key":"2024012713453873500_jbmr4335-bib-0019","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1177\/0141076819861027","article-title":"Hip fractures following denosumab discontinuation: three clinical case reports","volume":"112","author":"Sosa Henriquez","year":"2019","journal-title":"J R Soc Med."},{"issue":"9","key":"2024012713453873500_jbmr4335-bib-0020","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1007\/s00198-017-4080-6","article-title":"Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates","volume":"28","author":"Uebelhart","year":"2017","journal-title":"Osteoporos Int."},{"issue":"5","key":"2024012713453873500_jbmr4335-bib-0021","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00198-018-04820-8","article-title":"Alendronate after denosumab discontinuation in women previously exposed to bisphosphonates was not effective in preventing the risk of spontaneous multiple vertebral fractures: two case reports","volume":"30","author":"Lamy","year":"2019","journal-title":"Osteoporos Int."},{"key":"2024012713453873500_jbmr4335-bib-0022","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","article-title":"Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS","volume":"105","author":"Tsourdi","year":"2017","journal-title":"Bone."},{"key":"2024012713453873500_jbmr4335-bib-0023","doi-asserted-by":"crossref","DOI":"10.1097\/RHU.0000000000000979","article-title":"Spontaneous vertebral fractures in males with osteoporosis after denosumab discontinuation: a report of two cases","author":"Anagnostis","year":"2019","journal-title":"J Clin Rheumatol."},{"issue":"4","key":"2024012713453873500_jbmr4335-bib-0024","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00223-017-0288-x","article-title":"Bone loss after denosumab: only partial protection with zoledronate","volume":"101","author":"Reid","year":"2017","journal-title":"Calcif Tissue Int."},{"key":"2024012713453873500_jbmr4335-bib-0025","doi-asserted-by":"crossref","first-page":"115150","DOI":"10.1016\/j.bone.2019.115150","article-title":"Fracture incidence after denosumab discontinuation: real-world data from a large healthcare provider","volume":"130","author":"Tripto-Shkolnik","year":"2020","journal-title":"Bone."},{"key":"2024012713453873500_jbmr4335-bib-0026","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00223-019-00553-w","article-title":"Effect of zoledronate on bone loss after romosozumab\/denosumab: 2-year follow-up","volume":"105","author":"Horne","year":"2019","journal-title":"Calcif Tissue Int."},{"key":"2024012713453873500_jbmr4335-bib-0027","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","article-title":"Vertebral fracture assessment using a semiquantitative technique","volume":"8","author":"Genant","year":"2009","journal-title":"J Bone Miner Res."},{"issue":"6","key":"2024012713453873500_jbmr4335-bib-0028","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1530\/EJE-16-1027","article-title":"Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment","volume":"176","author":"Anastasilakis","year":"2017","journal-title":"Eur J Endocrinol."},{"key":"2024012713453873500_jbmr4335-bib-0029","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1007\/s00198-017-4108-y","article-title":"Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures","volume":"28","author":"Lehmann","year":"2017","journal-title":"Osteoporos Int."},{"issue":"7","key":"2024012713453873500_jbmr4335-bib-0030","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1002\/jbmr.3962","article-title":"Single infusion of zoledronate in postmenopausal women following denosumab discontinuation results in partial conservation of bone mass gains","volume":"35","author":"Everts-Graber","year":"2020","journal-title":"J Bone Miner Res."},{"key":"2024012713453873500_jbmr4335-bib-0031","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/jbmr.3370","article-title":"Underestimation of vertebral fractures after denosumab discontinuation","volume":"33","author":"Lamy","year":"2018","journal-title":"J Bone Miner Res."},{"key":"2024012713453873500_jbmr4335-bib-0032","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s00198-016-3829-7","article-title":"The lumbar spine age-related degenerative disease influences the BMD not the TBS: the osteolaus cohort","volume":"28","author":"Padlina","year":"2017","journal-title":"Osteoporos Int."},{"issue":"12","key":"2024012713453873500_jbmr4335-bib-0033","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1002\/jbmr.3853","article-title":"Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment. A prospective 2-year clinical trial","volume":"34","author":"Anastasilakis","year":"2019","journal-title":"J Bone Miner Res."},{"issue":"3","key":"2024012713453873500_jbmr4335-bib-0034","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1210\/clinem\/dgz095","article-title":"Bone mineral density after transitioning from denosumab to alendronate","volume":"105","author":"Kendler","year":"2020","journal-title":"J Clin Endocrinol Metab."}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jbmr.4335","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jbmr.4335","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/36\/9\/1717\/55454979\/jbmr4335.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/36\/9\/1717\/55454979\/jbmr4335.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T11:07:19Z","timestamp":1710328039000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/36\/9\/1717-1728\/7516550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,1]]},"references-count":34,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,5,19]]},"published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.4335","relation":{"has-review":[{"id-type":"doi","id":"10.1002\/JBMR.4335\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4335\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4335\/v3\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4335\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4335\/v3\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4335\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4335\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4335\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4335\/v1\/decision1","asserted-by":"object"}]},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12,1]]},"published":{"date-parts":[[2020,12,1]]},"assertion":[{"value":"2020-12-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}